Apparently You Also Make These Kind Of Mistakes With LY294002 !

Furthermore, erythropoietin levels are not readily interpreted in the individual SCD patient (McGonigle et?al, 1985; Sherwood et?al, 1986; Erslev et?al, 1987). Red cell precursor mass consumes erythropoietin and is an important determinant of erythropoietin levels (Stohlman & Brecher, 1959; Cazzola et?al, 1998; Veng-Pedersen et?al, 2002). Therefore, the increased red cell precursor mass necessary to maintain a given haemoglobin level in patients with a hemolytic disorder like SCD (Cazzola et?al, 1998; Fehr et?al, 2004) alters erythropoietin/haemoglobin correlations that have been described for the general population. Hence, measurement of erythropoietin levels could be useful in comparisons between groups for research purposes (as conducted http://www.selleckchem.com/products/CHIR-99021.html in this study), however, its utility for clinical decision making in the individual SCD patient is limited. Finally, in SCD patients whom are already http://www.selleck.cn/products/wortmannin.html anaemic and have decreased red cell survival, the consequences of small decrements in renal endocrine function are likely to be more severe than in the general population, underlining the importance of resolving or by-passing these diagnostic pitfalls. Here, the contribution of chronic relative reticulocytopenia (chRR, defined as haemoglobin http://www.selleckchem.com/products/LY294002.html as having a significant association with survival in adult patients with sickle cell anaemia [total hb, reticulocyte count, fetal haemoglobin %, white cell count (Platt et?al, 1994; Steinberg et?al, 2003)] and measurements informative of bone marrow and renal function (white cell count, platelet count, creatinine, urine protein and erythropoietin levels), were analysed. All laboratory data was generated in the UIC Clinical Pathology Laboratories using Clinical Laboratory Improvement Amendments (CLIA) approved methods. Analysed laboratory measurements were obtained in the outpatient clinic at least 4?weeks from an emergency room visit, hospital admission or blood transfusion. The most recent laboratory values available were used in the analysis of differences between patients with and without chRR. The first available laboratory haemoglobin, reticulocyte and serum creatinine values were used for stratification of patients for survival analysis. For survival analysis, age was age at first clinic visit.